Ask AI
ProCE Banner Activity

CELMoD Agents in Maintenance and Early-Relapse Settings for Multiple Myeloma

Slideset

Download this slideset featuring expert perspectives on the latest data and ongoing clinical trials with CELMoD agents for multiple myeloma.

Released: December 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate how differences in cereblon affinity and binding potency influence the antimyeloma activity of individual CELMoDs and IMiDs

  • Appraise emerging data for CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma

  • Assess the clinical implication and association of achieving MRD negativity on treatment as a surrogate marker of long-term outcomes

  • Identify patients with multiple myeloma who may be eligible for ongoing clinical trials of CELMoD-based therapies